A rehabilitation programme has been launched for cancer patients recovering from upper gastrointestinal, ovarian and bladder ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the ...
By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
InvestorsHub on MSN
Theralase and Ferring ink deal for new bladder cancer study
Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...
The Vancouver Sun on MSN
This made-in-B.C. preventive surgery lowers ovarian cancer risk
Opportunistic salpingectomy, or the removal of fallopian tubes in women already undergoing another abdominal or gynecological ...
ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...
Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...
Zacks.com on MSN
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of ...
Stocktwits on MSN
IBRX stock finds retail cheer after company’s immunotherapy for bladder cancer gets Saudi FDA approval
ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North ...
I was living a normal 29-year-old life. I thought my symptoms were no big deal, until they started happening more ...
Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback